Mon, June 4, 2012
Sat, June 2, 2012
Fri, June 1, 2012
Thu, May 31, 2012
Wed, May 30, 2012
Tue, May 29, 2012
Mon, May 28, 2012
Sun, May 27, 2012
Sat, May 26, 2012
Fri, May 25, 2012
[ Fri, May 25th 2012 ] - Market Wire
GenVec Reports Inducement Award
Thu, May 24, 2012
Wed, May 23, 2012
[ Wed, May 23rd 2012 ] - Market Wire
Moody's Upgrades Mylan
Tue, May 22, 2012

SciClone Pharmaceuticals to Present at Jefferies Global Healthcare Conference


//health-fitness.news-articles.net/content/2012/ .. t-at-jefferies-global-healthcare-conference.html
Published in Health and Fitness on Tuesday, May 29th 2012 at 13:05 GMT by Market Wire   Print publication without navigation


May 29, 2012 16:00 ET

SciClone Pharmaceuticals to Present at Jefferies Global Healthcare Conference

FOSTER CITY, CA--(Marketwire - May 29, 2012) - SciClone Pharmaceuticals, Inc. (NASDAQ: [ SCLN ]) today announced that Gary Titus, Chief Financial Officer, will present a corporate overview and business update at the Jefferies Global Healthcare Conference on June 5, 2012 at 9:30 am ET at the Grand Hyatt Hotel in New York City.

To access the live audio webcast of the presentation, please log on through a link located in the Investor Relations section of SciClone's website at [ www.sciclone.com ], under the Calendar of Events tab. A replay of the webcast will be available one hour after the conclusion of the live event.

About SciClone

SciClone Pharmaceuticals is a revenue-generating, profitable, specialty pharmaceutical company with a substantial commercial business in China and a product portfolio of therapies for oncology, infectious diseases and cardiovascular, urological, respiratory, and central nervous system disorders. SciClone's ZADAXIN® (thymalfasin) is approved in over 30 countries and may be used for the treatment of hepatitis B (HBV), hepatitis C (HCV), as a vaccine adjuvant, and certain cancers according to the local regulatory approvals. Besides ZADAXIN, SciClone markets about 15 mostly partnered products in China, including Depakine®, the most widely prescribed broad-spectrum anti-convulsant in China; Tritace®, an ACE inhibitor for the treatment of hypertension; Stilnox®, a fast-acting hypnotic for the short-term treatment of insomnia (marketed as Ambien® in the US); and Aggrastat®, a recently-launched interventional cardiology product. SciClone is also pursuing the registration of several other therapeutic products in China. SciClone is headquartered in Foster City, California. For additional information, please visit [ www.sciclone.com ].

Ambien, Depakine, Stilnox and Tritace are registered trademarks of Sanofi and/or its affiliates.

Aggrastat is a registered trademark of Medicure International Inc. in the United States, and Iroko Cardio LLC in numerous other countries.

SciClone, SciClone Pharmaceuticals, the SciClone Pharmaceuticals design, the SciClone logo and ZADAXIN are registered trademarks of SciClone Pharmaceuticals, Inc. in the United States and numerous other countries.



Publication Contributing Sources